LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 21

Search options

  1. Article ; Online: Air Pollution and the Novel Covid-19 Disease: a Putative Disease Risk Factor.

    Martelletti, Luigi / Martelletti, Paolo

    SN comprehensive clinical medicine

    2020  Volume 2, Issue 4, Page(s) 383–387

    Keywords covid19
    Language English
    Publishing date 2020-04-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2947211-8
    ISSN 2523-8973 ; 2523-8973
    ISSN (online) 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-020-00274-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Air Pollution and the Novel Covid-19 Disease

    Martelletti, Luigi / Martelletti, Paolo

    SN Comprehensive Clinical Medicine

    a Putative Disease Risk Factor

    2020  Volume 2, Issue 4, Page(s) 383–387

    Keywords covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2947211-8
    ISSN 2523-8973
    ISSN 2523-8973
    DOI 10.1007/s42399-020-00274-4
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Air pollution and the novel covid-19 disease. a putative disease risk factor

    Martelletti, Luigi / Martelletti, Paolo

    2020  

    Abstract: ... ...

    Abstract Editorial
    Keywords air pollution ; COVID-19 ; risk factors ; covid19
    Language English
    Publisher SpringerNature
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Association of COVID-19 distribution with air quality, sociodemographic factors, and comorbidities: an ecological study of US states.

    Sarmadi, Mohammad / Moghanddam, Vahid Kazemi / Dickerson, Aisha S / Martelletti, Luigi

    Air quality, atmosphere, & health

    2020  Volume 14, Issue 4, Page(s) 455–465

    Abstract: This ecological study investigated the association between COVID-19 distribution and air quality index (AQI), comorbidities and sociodemographic factors in the USA. The AQI factors included in the study are total AQI, ozone, carbon monoxide, sulfur ... ...

    Abstract This ecological study investigated the association between COVID-19 distribution and air quality index (AQI), comorbidities and sociodemographic factors in the USA. The AQI factors included in the study are total AQI, ozone, carbon monoxide, sulfur dioxide, and nitrogen dioxide (NO
    Keywords covid19
    Language English
    Publishing date 2020-10-14
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2424084-9
    ISSN 1873-9326 ; 1873-9318
    ISSN (online) 1873-9326
    ISSN 1873-9318
    DOI 10.1007/s11869-020-00949-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Association of COVID-19 distribution with air quality, sociodemographic factors, and comorbidities: an ecological study of US states

    Sarmadi, Mohammad / Moghanddam, Vahid Kazemi / Dickerson, Aisha S / Martelletti, Luigi

    Air Qual Atmos Health

    Abstract: This ecological study investigated the association between COVID-19 distribution and air quality index (AQI), comorbidities and sociodemographic factors in the USA. The AQI factors included in the study are total AQI, ozone, carbon monoxide, sulfur ... ...

    Abstract This ecological study investigated the association between COVID-19 distribution and air quality index (AQI), comorbidities and sociodemographic factors in the USA. The AQI factors included in the study are total AQI, ozone, carbon monoxide, sulfur dioxide, and nitrogen dioxide (NO2). Other demographic, socioeconomic, and geographic variables were included as covariates. The correlations of COVID-19 variables-proportion of cases and deaths in each population, as well as case fatality rate with independent variables were determined by Pearson and Spearman correlation and multiple linear regression analyses. The results revealed that AQI-NO2, population density, longitude, gross domestic product per capita, median age, total death of disease, and pneumonia per population were significantly associated with the COVID-19 variables (P < 0.05). Air pollutants, especially NO2 in the US case, could be addressed as an important factor linked with COVID-19 susceptibility and mortality.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #880347
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: A Critical Evaluation on MOH Current Treatments.

    Negro, Andrea / Curto, Martina / Lionetto, Luana / Guerzoni, Simona / Pini, Luigi Alberto / Martelletti, Paolo

    Current treatment options in neurology

    2017  Volume 19, Issue 9, Page(s) 32

    Abstract: Opinion statement: Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients ... ...

    Abstract Opinion statement: Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM). CM is characterized by high frequency of the attacks that may result into chronic intake of abortive medications. Nearly, the 70% of CM patients referring to tertiary head centers show acute pain medications overuse that may lead to the development of medication overuse headache (MOH). The management of MOH requires three steps: (1) education, (2) withdrawal of the overuse drug and detoxification, and (3) re-prophylaxis. In the last years, several real-life prospective studies provided further evidence in clinical setting of the onabotulinumtoxinA 155-195 U efficacy for the headache prophylaxis in CM with MOH patients. There is a general agreement on two factors: (1) withdrawal of the overuse drug is condicio sine qua non to reverse the pattern to medium-low-frequency migraine, and (2) the focus of management needs to shift from acute treatment of pain to prevention of headache. CM patients close to developing MOH, patients with high-frequency episodic migraine, and those already abusing of drugs require special attention and should refer to tertiary headache centers. For all of them, a solution could be an "early treatment." Early should be their referral to a tertiary headache center, early should be the withdrawal of the overuse drug and a proper detoxification, and perhaps early should be the start of a preventative therapy.
    Language English
    Publishing date 2017-08-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057342-X
    ISSN 1534-3138 ; 1092-8480
    ISSN (online) 1534-3138
    ISSN 1092-8480
    DOI 10.1007/s11940-017-0465-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5535: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.

    Guerzoni, Simona / Pellesi, Lanfranco / Baraldi, Carlo / Cainazzo, Michela Maria / Negro, Andrea / Martelletti, Paolo / Pini, Luigi Alberto

    Frontiers in neurology

    2017  Volume 8, Page(s) 586

    Abstract: Background: Chronic migraine (CM) affects about the 2% of the general population and it has been recognized as one of the most-disabling conditions worldwide by the World Health Organization. CM is often associated with the overuse of abortive ... ...

    Abstract Background: Chronic migraine (CM) affects about the 2% of the general population and it has been recognized as one of the most-disabling conditions worldwide by the World Health Organization. CM is often associated with the overuse of abortive medication, which determines the worsening of headache itself and the development of a secondary headache called medication overuse headache. The management of these associated conditions is difficult, but a growing amount of evidence is pointing out the effectiveness and the good safety profile of OnabotulinumtoxinA (OnabotA). Despite this, data on OnabotA effects and safety in long-term use lack. The purpose of the present article is to retrospectively assess the efficacy and safety of OnabotA in a cohort of chronic migraineurs with drug overuse from the 18th month of treatment until the third year.
    Materials and methods: 90 chronic migraineurs with medication overuse were enrolled between January 2013 and February 2017. All patients were treated with OnabotA according to PREEMPT dictates. Before every injection session the headache index, the analgesic consumption, the visual analog scale for pain score, the 36-items short form health survey questionnaire score, the 6-items headache impact test (HIT-6) score and the Zung self-rating anxiety and depression scale scores were collected. Adverse events were carefully registered. A simple linear regression was performed to explore the mean changes in the abovementioned parameters for a single injection session and mean comparison tests were performed using the one-way analysis of variance followed by Tukey-Kramer post-hoc test.
    Results: A significantly improvement for a single injection was registered for all the above-mentioned parameters. Headache index, analgesic consumption, visual analog pain scale, and 6-items HIT-6 scores were significantly lower than baseline from the 18th month of treatment onwards. The 36-items short form health survey questionnaire scores were significantly higher than baseline at every injections session from the 18th months onwards. Zung scales did not change. No serious adverse events were assessed and no adverse events-related drop-outs were seen.
    Conclusion: OnabotA effectiveness and safety last until 3 years of therapy, raising the possibility of the use of this therapy even for many years in CM prevention.
    Language English
    Publishing date 2017-11-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2017.00586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

    Agostoni, Elio Clemente / Barbanti, Piero / Calabresi, Paolo / Colombo, Bruno / Cortelli, Pietro / Frediani, Fabio / Geppetti, Pietrangelo / Grazzi, Licia / Leone, Massimo / Martelletti, Paolo / Pini, Luigi Alberto / Prudenzano, Maria Pia / Sarchielli, Paola / Tedeschi, Gioacchino / Russo, Antonio

    The journal of headache and pain

    2019  Volume 20, Issue 1, Page(s) 92

    Abstract: Background: Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological ... ...

    Abstract Background: Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment.
    Findings: Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment.
    Conclusions: Treatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Botulinum Toxins, Type A/therapeutic use ; Chronic Disease ; Disabled Persons ; Humans ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Randomized Controlled Trials as Topic ; Topiramate/therapeutic use
    Chemical Substances Antibodies, Monoclonal ; Topiramate (0H73WJJ391) ; Botulinum Toxins, Type A (EC 3.4.24.69)
    Language English
    Publishing date 2019-08-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2036768-5
    ISSN 1129-2377 ; 1129-2369
    ISSN (online) 1129-2377
    ISSN 1129-2369
    DOI 10.1186/s10194-019-1038-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5464: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.

    Tassorelli, Cristina / Tedeschi, Gioacchino / Sarchielli, P / Pini, Luigi Alberto / Grazzi, Licia / Geppetti, Pierangelo / De Tommaso, Marina / Aguggia, Marco / Cortelli, P / Martelletti, Paolo

    Expert review of neurotherapeutics

    2017  Volume 18, Issue 2, Page(s) 167–176

    Abstract: Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. ...

    Abstract Introduction: Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.
    MeSH term(s) Acetylcholine Release Inhibitors/therapeutic use ; Botulinum Toxins, Type A/therapeutic use ; Chronic Disease ; Drug Administration Schedule ; Humans ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Patient Education as Topic ; Prescription Drug Overuse
    Chemical Substances Acetylcholine Release Inhibitors ; Botulinum Toxins, Type A (EC 3.4.24.69) ; onabotulinum toxin A (EC 3.4.24.69)
    Language English
    Publishing date 2017-12-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1080/14737175.2018.1419867
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top